Drugs / MenACWY-DT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT03694405 | Sep 2018 → Aug 2021 | meningococcal infection | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT02864927 | Jul 2016 → Jun 2019 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03691610 Comparator | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY-DT | “The meningococcal (groups A, C, Y, and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-DT, Menactra®) was licensed in the Republic of Korea in 2014.” PMID 33439463 ↗ Jan 20212“Toddlers were randomized 1:1 to receive MenACYW-TT (Group 3) or another quadrivalent conjugate vaccine, MenACWY-DT (Group 4) at ages 17-19 and 20-23 months.” PMID 41792337 ↗ Mar 2026 |
| Modality | Vaccine | “polysaccharide diphtheria toxoid conjugate vaccine” NCT02864927 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02864927 ↗ |